RU2013103535A - Иммортализованная клеточная линия птиц - Google Patents

Иммортализованная клеточная линия птиц Download PDF

Info

Publication number
RU2013103535A
RU2013103535A RU2013103535/10A RU2013103535A RU2013103535A RU 2013103535 A RU2013103535 A RU 2013103535A RU 2013103535/10 A RU2013103535/10 A RU 2013103535/10A RU 2013103535 A RU2013103535 A RU 2013103535A RU 2013103535 A RU2013103535 A RU 2013103535A
Authority
RU
Russia
Prior art keywords
virus
specified
cell line
ecacc
derivatives
Prior art date
Application number
RU2013103535/10A
Other languages
English (en)
Inventor
Филипп ЭРБ
Марина КАПФЕР
Натали СИЛЬВЕСТР
Original Assignee
Трансген Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Трансген Са filed Critical Трансген Са
Publication of RU2013103535A publication Critical patent/RU2013103535A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24051—Methods of production or purification of viral material
    • C12N2710/24052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1. Иммортализованная линия клеток птиц, депонированная в Европейской коллекции клеточных культур (ЕСАСС) под номером доступа 09070701, и ее производные.2. Иммортализованная линия клеток птиц, депонированная в Европейской коллекции клеточных культур (ЕСАСС) под номером доступа 09070702, и ее производные.3. Иммортализованная линия клеток птиц, депонированная в Европейской коллекции клеточных культур (ЕСАСС) под номером доступа 09070703, и ее производные.4. Иммортализованная клетка птиц по любому из пп.1-3, дополнительно включающая в себя одну или более нуклеотидную последовательность, делающую возможным размножение дефектных вирусов.5. Иммортализованная линия клеток птиц по любому из пп.1-3, дополнительно включающая нуклеотидную последовательность, кодирующую целевое вещество.6. Способ репликации вируса, где указанный способ включает применение иммортализованной линии клеток птиц по любому из пп.1-3.7. Способ по п.6, где указанный вирус представляет собой живой вирус, аттенуированный вирус или рекомбинантный вирус.8. Способ по п.6, где указанный вирус выбран из группы, включающей поксвирус, аденовирус, ретровирус, вирус герпеса, альфавирус, вирус пенистости, аденоассоциированный вирус, флавивирус и вирус гриппа.9. Способ по п.8, где указанный вирус представляет собой поксвирус.10. Способ по п.9, где указанный вирус представляет собой вирус осповакцины.11. Способ по п.10, где указанный вирус представляет собой модифицированный вирус осповакцины Ankara (MVA).12. Способ по п.10, где указанный вирус представляет собой штамм Copenhagen вируса осповакцины.13. Способ по п.8, где указанный вирус представляет собой вирус гриппа типа A.14. Способ по п.13, где указа�

Claims (16)

1. Иммортализованная линия клеток птиц, депонированная в Европейской коллекции клеточных культур (ЕСАСС) под номером доступа 09070701, и ее производные.
2. Иммортализованная линия клеток птиц, депонированная в Европейской коллекции клеточных культур (ЕСАСС) под номером доступа 09070702, и ее производные.
3. Иммортализованная линия клеток птиц, депонированная в Европейской коллекции клеточных культур (ЕСАСС) под номером доступа 09070703, и ее производные.
4. Иммортализованная клетка птиц по любому из пп.1-3, дополнительно включающая в себя одну или более нуклеотидную последовательность, делающую возможным размножение дефектных вирусов.
5. Иммортализованная линия клеток птиц по любому из пп.1-3, дополнительно включающая нуклеотидную последовательность, кодирующую целевое вещество.
6. Способ репликации вируса, где указанный способ включает применение иммортализованной линии клеток птиц по любому из пп.1-3.
7. Способ по п.6, где указанный вирус представляет собой живой вирус, аттенуированный вирус или рекомбинантный вирус.
8. Способ по п.6, где указанный вирус выбран из группы, включающей поксвирус, аденовирус, ретровирус, вирус герпеса, альфавирус, вирус пенистости, аденоассоциированный вирус, флавивирус и вирус гриппа.
9. Способ по п.8, где указанный вирус представляет собой поксвирус.
10. Способ по п.9, где указанный вирус представляет собой вирус осповакцины.
11. Способ по п.10, где указанный вирус представляет собой модифицированный вирус осповакцины Ankara (MVA).
12. Способ по п.10, где указанный вирус представляет собой штамм Copenhagen вируса осповакцины.
13. Способ по п.8, где указанный вирус представляет собой вирус гриппа типа A.
14. Способ по п.13, где указанный вирус гриппа типа A выбран из группы, включающей штаммы H1N1 и H3N2.
15. Способ по п.8, где указанный вируса гриппа относится к типу B.
16. Способ по п.15, где указанный вирус гриппа типа B выбран из группы, включающей штаммы Brisbane и Florida.
RU2013103535/10A 2010-07-02 2011-06-29 Иммортализованная клеточная линия птиц RU2013103535A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/829,773 US8357531B2 (en) 2007-07-03 2010-07-02 Immortalized avian cell lines
US12/829,773 2010-07-02
PCT/EP2011/060952 WO2012001075A2 (en) 2010-07-02 2011-06-29 Immortalized avian cell lines

Publications (1)

Publication Number Publication Date
RU2013103535A true RU2013103535A (ru) 2014-08-10

Family

ID=44629571

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013103535/10A RU2013103535A (ru) 2010-07-02 2011-06-29 Иммортализованная клеточная линия птиц

Country Status (11)

Country Link
US (2) US8357531B2 (ru)
EP (1) EP2588596A2 (ru)
JP (1) JP2013529921A (ru)
KR (1) KR20130030298A (ru)
CN (1) CN103328628A (ru)
AU (1) AU2011273520A1 (ru)
BR (1) BR112012033538A2 (ru)
CA (1) CA2803509A1 (ru)
MX (1) MX2013000136A (ru)
RU (1) RU2013103535A (ru)
WO (1) WO2012001075A2 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
JP6333814B2 (ja) 2012-07-10 2018-05-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マイコバクテリア抗原ワクチン
JP6605480B2 (ja) 2014-01-09 2019-11-13 トランスジェン・ソシエテ・アノニム ヘテロオリゴマーマイコバクテリア抗原の融合物
US10555981B2 (en) 2014-07-16 2020-02-11 Transgene S.A. Oncolytic virus for expression of immune checkpoint modulators
KR101645642B1 (ko) * 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3038324B1 (fr) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN110168092A (zh) 2016-12-28 2019-08-23 特朗斯吉有限公司 溶瘤病毒和治疗分子
CN111065406A (zh) 2017-06-21 2020-04-24 特兰斯吉恩股份有限公司 个性化疫苗
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
FR3089789B1 (fr) * 2018-12-14 2022-05-27 Univ Claude Bernard Lyon Production de vaccins viraux sur une lignee cellulaire aviaire
MX2021007860A (es) 2018-12-28 2021-10-26 Transgene Poxvirux deficiente en m2.
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
EP0941066B1 (en) 1996-08-26 2003-10-29 Transgene S.A. Cationic lipid-nucleic acid complexes
FR2754824B1 (fr) 1996-10-23 1999-03-05 Transgene Sa Nouvelle composition contenant du chitosan
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
AU707186B2 (en) 1997-07-01 1999-07-01 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
FR2766195A1 (fr) 1997-07-21 1999-01-22 Transgene Sa Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
CA2532783C (en) 2003-07-21 2013-09-17 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
EP1646715B1 (en) 2003-07-22 2010-05-12 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
US9024003B2 (en) * 2006-01-05 2015-05-05 Transgene S.A. Avian telomerase reverse transcriptase
BRPI0811787B1 (pt) * 2007-07-03 2018-10-09 Transgene Sa usos de uma célula imortalizada e processo para imortalizar uma célula aviária

Also Published As

Publication number Publication date
CA2803509A1 (en) 2012-01-05
US20120238000A1 (en) 2012-09-20
AU2011273520A1 (en) 2013-02-07
WO2012001075A2 (en) 2012-01-05
MX2013000136A (es) 2013-03-18
WO2012001075A3 (en) 2012-02-23
BR112012033538A2 (pt) 2018-08-07
EP2588596A2 (en) 2013-05-08
CN103328628A (zh) 2013-09-25
KR20130030298A (ko) 2013-03-26
US8357531B2 (en) 2013-01-22
US8513018B2 (en) 2013-08-20
US20110008872A1 (en) 2011-01-13
JP2013529921A (ja) 2013-07-25

Similar Documents

Publication Publication Date Title
RU2013103535A (ru) Иммортализованная клеточная линия птиц
Kennedy et al. IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccine
Zhou et al. Outbreak of myelocytomatosis caused by mutational avian leukosis virus subgroup J in China, 2018
Uzcategui et al. Rate of evolution and molecular epidemiology of tick-borne encephalitis virus in Europe, including two isolations from the same focus 44 years apart
BRPI1007743A2 (pt) Linhagens de célula aviária imortalizada, usos de uma linhagem de célula aviária imortalizada, métodos para a produção de vírus e métodos para a produção de proteína
BR112018013168A2 (pt) vírus mutantes, método de preparação e uso dos mesmos
Ramey et al. Evidence for common ancestry among viruses isolated from wild birds in Beringia and highly pathogenic intercontinental reassortant H5N1 and H5N2 influenza A viruses
Jiang et al. Molecular characterization and phylogenetic analysis of the reticuloendotheliosis virus isolated from wild birds in Northeast China
Li et al. Avian leukosis virus subgroup A and B infection in wild birds of Northeast China
RS54231B1 (en) NEW EUROPEAN SOY
Zhang et al. A single amino acid at residue 188 of the hexon protein is responsible for the pathogenicity of the emerging novel virus fowl adenovirus 4
Kwon et al. Domestic ducks play a major role in the maintenance and spread of H5N8 highly pathogenic avian influenza viruses in South Korea
Yu et al. Isolation and genetic characterization of avian-like H1N1 and novel ressortant H1N2 influenza viruses from pigs in China
Zhang et al. Genetic and pathogenic characteristics of newly emerging avian reovirus from infected chickens with clinical arthritis in China
WO2005115448A8 (en) Multi plasmid system for the production of influenza virus
Mardani et al. Naturally occurring recombination between distant strains of infectious bronchitis virus
Lee et al. Experimental infection of SPF and Korean native chickens with highly pathogenic avian influenza virus (H5N8)
Abdollahi et al. Spatial spread and emergence of reassortant H5 highly pathogenic avian influenza viruses in Iran
Poetranto et al. An H5N1 highly pathogenic avian influenza virus isolated from a local tree sparrow in Indonesia
Li et al. High genetic diversity of Tibetan Mastiffs revealed by mtDNA sequences
Lee et al. Intercontinental spread of Asian-origin H7 avian influenza viruses by captive bird trade in 1990's
Promkuntod et al. Analysis of the S1 gene of the avian infectious bronchitis virus (IBV) reveals changes in the IBV genetic groups circulating in southern Thailand
Munyahongse et al. Genetic characterization of infectious bronchitis viruses in Thailand, 2014–2016: Identification of a novel recombinant variant
BRPI0922788B8 (pt) composição para uso no crescimento de culturas virais e kit para cultura de vírus
Wang et al. Construction of a peacock immortalized fibroblast cell line for avian virus production

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20151007